UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Multi-output Gaussian Process Regression Model with Combined Kernel Function for Polyester Esterification Processes

东华大学学报（英文版）, 2023, Vol.40 (1), p.27-33

2023

Volltextzugriff (PDF)

Efficacy-Driven Dose Finding with Toxicity Control in Phase I Oncology Studies

Statistics in biosciences, 2022-12, Vol.14 (3), p.413-431

2022

Volltextzugriff (PDF)

Development of a hydrogen peroxide-responsive and oxygen-carrying nanoemulsion for photodynamic therapy against hypoxic tumors using phase inversion composition method

Journal of innovative optical health science, 2021-03, Vol.14 (2), p.2150003-1-2150003-9

2021

Volltextzugriff (PDF)

Probabilistic Community Detection With Unknown Number of Communities

Journal of the American Statistical Association, 2019-04, Vol.114 (526), p.893-905

2019

Volltextzugriff (PDF)

Heterogeneity learning for SIRS model: an application to the COVID-19

Statistics and its interface, 2021, Vol.14 (1), p.73-81

2021

Volltextzugriff (PDF)

Bayesian Spatial Homogeneity Pursuit of Functional Data: An Application to the U.S. Income Distribution

Bayesian analysis, 2023-06, Vol.18 (2)

2023

Volltextzugriff (PDF)

Bayesian nonparametric nonhomogeneous Poisson process with applications to USGS earthquake data

Spatial statistics, 2021-03, Vol.41, p.100495, Article 100495

2021

Volltextzugriff (PDF)

An exploration of National Weather Service daily forecasts using R Shiny

Computational statistics, 2023-09, Vol.38 (3), p.1173-1191

2023

Volltextzugriff (PDF)

The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

Cancer discovery, 2023-08, Vol.13 (8), p.1802-1813

2023

Volltextzugriff (PDF)

Efficacy and safety of brigimadlin (BI 907828), an MDM2–p53 antagonist, in patients (pts) with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.487-487

2024

Volltextzugriff (PDF)

A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 (ezabenlimab) and BI 754111 in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3095-3095

2022

Volltextzugriff (PDF)

Longitudinal mutational analysis of TP53 in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, an MDM2–p53 antagonist

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3036-3036

2023

Volltextzugriff (PDF)

A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.11554-11554

2023

Volltextzugriff (PDF)

Efficacy and safety of the MDM2–p53 antagonist BI 907828 in patients with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.543-543

2023

Volltextzugriff (PDF)

A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine neoplasms expressing DLL3

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS8588-TPS8588

2021

Volltextzugriff (PDF)

A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma (LPS)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3004-3004

2022

Volltextzugriff (PDF)

A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3016-3016

2021

Volltextzugriff (PDF)

Estimands in Oncology Early Clinical Development: Assessing the Impact of Intercurrent Events on the Dose-Toxicity Relationship

Statistics in biopharmaceutical research, 2024-01, p.1-9

2024

Volltextzugriff (PDF)

Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin

OncoTargets and therapy, 2024-03, Vol.17, p.267

2024

Volltextzugriff (PDF)

A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS3166-TPS3166

2019

Volltextzugriff (PDF)

Pharmacokinetics-Guided Dose Allocation in Comparison with Binary Dose Spacing

Statistics in biosciences, 2019-12, Vol.11 (3), p.677-693

2019

Volltextzugriff (PDF)

Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series

OncoTargets and therapy, 2024-01, Vol.17, p.267-280

2024

Volltextzugriff (PDF)

Bayesian Models for Capturing Heterogeneity in Discrete Data

Geng, Junxian

2017

Volltextzugriff (PDF)

Fractal-based combined kernel function model for the polyester polymerization process

2021 33rd Chinese Control and Decision Conference (CCDC), 2021, p.656-661

2021

Volltextzugriff (PDF)

Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series

OncoTargets and therapy, 2024, Vol.17, p.267-280

2024

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(51)

Publikationsform

Sprache

Englisch
(57)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Multi-output Gaussian Process Regression Model with Combined Kernel Function for Polyester Esterification Processes

Efficacy-Driven Dose Finding with Toxicity Control in Phase I Oncology Studies

Development of a hydrogen peroxide-responsive and oxygen-carrying nanoemulsion for photodynamic therapy against hypoxic tumors using phase inversion composition method

Probabilistic Community Detection With Unknown Number of Communities

Heterogeneity learning for SIRS model: an application to the COVID-19

Bayesian Spatial Homogeneity Pursuit of Functional Data: An Application to the U.S. Income Distribution

Bayesian nonparametric nonhomogeneous Poisson process with applications to USGS earthquake data

An exploration of National Weather Service daily forecasts using R Shiny

The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

Efficacy and safety of brigimadlin (BI 907828), an MDM2–p53 antagonist, in patients (pts) with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials

A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 (ezabenlimab) and BI 754111 in patients (pts) with advanced solid tumors

Longitudinal mutational analysis of TP53 in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, an MDM2–p53 antagonist

A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS)

Efficacy and safety of the MDM2–p53 antagonist BI 907828 in patients with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials

A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine neoplasms expressing DLL3

A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma (LPS)

A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors

Estimands in Oncology Early Clinical Development: Assessing the Impact of Intercurrent Events on the Dose-Toxicity Relationship

Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin

A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors

Pharmacokinetics-Guided Dose Allocation in Comparison with Binary Dose Spacing

Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series

Bayesian Models for Capturing Heterogeneity in Discrete Data

Fractal-based combined kernel function model for the polyester polymerization process

Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series

Suchergebnisse filtern